AGC to triple US capacity with $88mn investment

By hotmaillogin

Tokyo-based manufacturer of glass, chemicals and high tech materials, AGC Inc, announced today its plans to triple its biopharmaceutical production capacity in the United States through a major expansion of its subsidiary AGC Biologics.

While currently, AGC Biologics only possesses manufacturing infrastructure in Japan and Europe, plans were this week finalized to construct a major new facility in Seattle, Washington, as well as to expand the company’s current facilities in the city. The project will involve the installation of 12 additional 2,000L single-use mammalian cell bioreactors, as well as the construction of a new microbial contract development and manufacturing facility.

The new facilities are expected to start operating in July, 2020, and the total cost of the expansion is predicted to be in the realm of US$88mn.



This project continues a trend of expansion by AGC and its subsidiaries. In 2016 the company acquired German pharmaceutical manufacturer Biomeva, and CMC Biologics in 2017.

AGC intends to continue to pursue acquisition opportunities and to make capital investment in its synthetic and biopharmaceutical business,” said a company press release, “expected to exhibit significant growth in demand in the coming years, in order to continue providing customers in every region with globally consistent, top-level quality and service.


Featured Articles

JPMorgan Chase: Committed to supporting the next generation

JPMorgan has unveiled a host of new and expanded philanthropic activities totalling US$3.5 million to support the development of apprenticeship programmes

How efficient digital ecosystems became business critical

During this unprecedented era of rapid digital transformation, establishing a well-functioning ecosystem stands to benefit both employees and customers

Mastercard: Supporting clients at a time of rapid evolution

Mastercard has announced a significant expansion of its consulting business with the launch of new practices dedicated to both AI and economics

Why Ceridian has boldly rebranded to Dayforce

Human Capital

McKinsey’s eight lessons in leadership for aspiring CEOs

Leadership & Strategy

KPMG: The biggest challenges facing global CEOs in 2023

Leadership & Strategy